News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML
Naveen Pemmaraju/mdanderson.org
Apr 29, 2025, 09:33

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared an article by Naval Daver, et al. on X:

“Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by Naval Daver and Hussein Abbas.”

Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis.

Journal: Clinical Cancer Research.

Authors: Naval Daver, et al.

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

More posts featuring Naveen Pemmaraju.

AML azacitidine BPDCN Program cancer fight against cancer Global fight against cancer Hussein Abbas magrolimab MD Anderson Cancer Center Naval Daver Naveen Pemmaraju OncoDaily Oncology University of Texas venetoclax
Special Coverage
Immune Oncology
Aug 24, 2025, 08:42
10 Must-Read Posts in Immuno-Oncology This Week
Voices
Aug 24, 2025, 08:34
Arturo LoAIza-Bonilla Discusses AI in Cancer at Sylvester Comprehensive Cancer Center
Insight
Aug 24, 2025, 08:27
Roupen Odabashian: Review of OpenEvidence AI Scribe
Voices
Aug 24, 2025, 08:18
Registration Is Open for the Annual Hematologic Malignancies Congress - NCCN
Voices
Aug 24, 2025, 07:53
Carmen Monge-Montero: A Glimpse of the Powerful Conversation with Michael Holtz
Insight
Aug 24, 2025, 07:51
Kefah Mokbel: Update on the Management of Phyllodes Tumours
Voices
Aug 24, 2025, 07:38
Spotlight on Tenaye Alazar, Program Coordinator in Ethiopia - The Max Foundation
Insight
Aug 24, 2025, 07:13
Olivier Elemento: AI in Hematology - A 2025 Snapshot from ASH
Insight
Aug 24, 2025, 07:09
Arturo LoAIza-Bonilla: Co-Authoring Insights on Large Language Models in Radiation Oncology
Drugs
Aug 24, 2025, 05:59
Lonsurf (Trifluridine/Tipiracil): A Patient’s Guide 2025 to Treatment for Advanced Colorectal and Stomach Cancer
Drugs
Aug 24, 2025, 05:22
Lonsurf (trifluridine/tipiracil) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More
Blog Posts
Aug 24, 2025, 05:05
Naveen Pemmaraju: Wonderful to Meet Friends and Colleagues at MPN meeting 2025